Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

被引：0
|
作者：
O'Shaughnessy, J. [1 ]
Wright, G. S. [2 ]
Thummala, A. [3 ]
Danso, M. [4 ]
Popovic, L. S. [5 ]
Pluard, T. [6 ]
Han, H. S. [7 ]
Vojnovic, Z. [8 ]
Vasev, N. [9 ]
Ma, L. [10 ]
Richards, D. A. [11 ]
Wilks, S. [12 ]
Milenkovic, D. M. [13 ]
Sorrentino, J. A. [14 ]
Yang, Z. [15 ]
Horton, J. K. [16 ]
Tan, A. R. [17 ]
机构：
[1] Texas Oncol Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[2] Florida Canc Specialists, Oncol, St Petersburg, FL USA
[3] US Oncol Res, Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[4] Virginia Oncol Associates, Med Oncol, Norfolk, VA USA
[5] Oncol Inst Vojvodina, Med Oncol, Sremska Kamenica, Serbia
[6] St Lukes Primary Care Plaza, Med Oncol, Kansas City, MO USA
[7] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Breast Oncol, Tampa, FL USA
[8] OB Opca Boln Varazdin Gen Hosp, Dept Oncol, Varazhdin, Croatia
[9] UCRO, Dept Oncol, Skopje, Macedonia
[10] Rocky Mt Canc Ctr LLP, Med Oncol, Denver, CO USA
[11] Texas Oncol PA, Med Oncol, Houston, TX USA
[12] Texas Oncol San Antonio Northeast, Med Oncol, San Antonio, TX USA
[13] Univ Nis, Clin Ctr Nis, Clin Oncol, Nish, Serbia
[14] G1 Therapuet Inc, Translat Med, Res Triangle Pk, NC USA
[15] G1 Therapuet Inc, Biostat, Res Triangle Pk, NC USA
[16] G1 Therapuet Inc, Clin Dev, Res Triangle Pk, NC USA
[17] Atrium Hlth, Levine Canc Inst, Med Oncol, Charlotte, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA22
引用
收藏
页码：860 / +
页数：2
相关论文
共 50 条
  • [21] Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
    Veitch, Zachary William Neil
    Cescon, David W.
    Elston, Sawako
    Lien, Scott
    Yang, Cindy
    Wang, Ben X.
    Berman, Hal K.
    Butler, Marcus O.
    Amir, Eitan
    Elser, Christine
    Hakgor, Sevan
    Giesler, Amanda
    Pugh, Trevor John
    Ohashi, Pamela S.
    Siu, Lillian L.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?
    Bajaj, P.
    Latremouille-Viau, D.
    Guerin, A.
    Reyes, C.
    Stein, A.
    Kurian, A.
    Cortazar, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Trippa, Lorenzo
    Li, Tianyu
    Keenan, Tanya E.
    Winship, Grace
    Andrews, Chelsea
    Osmani, Wafa
    Overmoyer, Beth
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Duda, Dan G.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [25] Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Novik, Yelena
    Speyer, James L.
    Meyers, Marlene
    Adams, Sylvia
    Omene, Coral Oghenerukevwe
    Muggia, Franco
    Schneider, Robert
    Formenti, Silvia
    Davis, Samantha
    Beardslee, Brian
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Winship, Grace
    Overmoyer, Beth
    Duda, Dan G.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response
    Hirshfield, Kim M.
    Lu, Shou-En
    Wong, Serena
    Tan, Antoinette
    Kirstein, Laurie
    Kearney, Thomas
    Shih, Weichung
    Ganesan, Shridar
    Toppmeyer, Deborah L.
    CANCER RESEARCH, 2015, 75
  • [28] A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
    Cowherd, S.
    Miller, L. D.
    Melin, S. A.
    Akman, S.
    Isom, S.
    Cole, J.
    Pullikuth, A.
    Lawrence, J. A.
    CANCER BIOLOGY & THERAPY, 2015, 16 (05) : 678 - 683
  • [29] Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
    Tan, Antoinette R.
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Xiao, Jie
    Sorrentino, Jessica
    Horton, Janet
    O'Shaughnessy, Joyce
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 629 - 636
  • [30] Carboplatin and Gemcitabine Combination in Metastatic Triple-Negative Anthracycline- and Taxane-Pretreated Breast Cancer Patients: A Phase II Study
    Maisano, R.
    Zavettieri, M.
    Azzarello, D.
    Raffaele, M.
    Maisano, M.
    Bottari, M.
    Nardi, M.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 40 - 43
12345